<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04764006</url>
  </required_header>
  <id_info>
    <org_study_id>HMPL-012-SPRING-C101</org_study_id>
    <nct_id>NCT04764006</nct_id>
  </id_info>
  <brief_title>Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study</brief_title>
  <official_title>A Single Arm, Open-label, Single Center Phase II Study of Surufatinib Combined With PD-1 in Patients With Advanced MSS-Type Colorectal Cancer Treated With Standard First-line Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II study to assess the efficacy and safety of Surufatinib combined with Sintilimab as&#xD;
      a second-line treatment in patients with advanced MSS-Type CRC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>CR + PR rate according to the RECIST version 1.1 guidelines.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>To assess the efficacy of Surufatinib Combined With Chemotherapy as second-line therapy to Advanced CRC, patients by assessment of progression free survival (PFS) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival time</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Disease control rate (DCR):CR + PR + SD rate according to the RECIST version 1.1 guidelines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the anti-tumor activity:DCR</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Disease control rate (DCR):CR + PR + SD rate according to the RECIST version 1.1 guidelines.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Advanced Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Surufatinib plus Sintilimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Surufatinib plus Sintilimab Surufatinib will be given orally. Sintilimab will be given intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surufatinib</intervention_name>
    <description>Surufatinib(250mg ,qd,po)+Sintilimab(200mg,q3w,iv),21 days for a cycle.The curative effect was evaluated every 8 weeks.</description>
    <arm_group_label>Surufatinib plus Sintilimab</arm_group_label>
    <other_name>HMPL-012</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. For inclusion in study, patient must provide a written informed consent.&#xD;
&#xD;
          2. Male or female, age18-75 years.&#xD;
&#xD;
          3. Pathologically confirmed unresectable locally advanced or advanced MSS-Type metastatic&#xD;
             colorectal adenocarcinoma .&#xD;
&#xD;
          4. The patient had previously failed standard first-line systemic chemotherapy,Prior&#xD;
             adjuvant and neo-adjuvant therapy is permitted (chemotherapy, radiotherapy,&#xD;
             investigational agents) if 6 months or more have passed since completion of therapy.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1.&#xD;
&#xD;
          6. Life expectancy &gt; 12 weeks.&#xD;
&#xD;
          7. Have measurable disease based on RECIST 1.1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any therapy with anti-PD-1, or anti-PD-L1/l2 antibodies or anti-cytotoxic T lymphocyte&#xD;
             associated antigen-4 (CTLA-4) antibody (or any other antibody acting on T cell&#xD;
             costimulatory or checkpoint pathway) or fruquintinib treatment in previous.&#xD;
&#xD;
          2. Prior receipt of Surufatinib.&#xD;
&#xD;
          3. History of any active autoimmune disease or autoimmune disease, including but not&#xD;
             limited to interstitial pneumonia, uveitis, inflammatory bowel disease, hepatitis,&#xD;
             pituitary inflammation, vasculitis, systemic lupus erythematosus, etc. (except&#xD;
             patients with hypothyroidism that can be controlled only by hormone replacement&#xD;
             therapy and patients with type I diabetes who only need insulin replacement therapy).&#xD;
&#xD;
          4. History of gastrointestinal perforation and/or fistula, ileus, inflammatory bowel&#xD;
             disease, or extensive enterotomy (partial colectomy or extensive enterotomy with&#xD;
             chronic diarrhea), Crohn's disease, ulcerative colitis, or chronic diarrhea within 6&#xD;
             months prior to first dosing.&#xD;
&#xD;
          5. Any life-threatening bleeding event or grade 3 or 4 bleeding requiring blood&#xD;
             transfusion, endoscopy, or surgery with 3 months prior to dosing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zengqing Guo</last_name>
    <phone>86-13905918836</phone>
    <email>gzq_005@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>China, Fujian</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zengqing Guo, MD</last_name>
      <phone>8613905918836</phone>
      <email>gzq_005@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 18, 2021</study_first_submitted>
  <study_first_submitted_qc>February 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

